We, as a matter of course, do meet with patient advocacy groups. As a matter of course, we meet with industry and industry groups. So the process is already in place; it was started at the beginning for CDR. At the very beginning of CDR we had consultation sessions with both those groups, and we continue to talk to those groups.
There is a place for input from everywhere, but I feel I'm compelled to point out for the committee that the stakes for the industry are huge. The amount spent in Canada on drugs is over $20 billion. On prescription drugs alone, it's $17 billion. The stakes are huge. We all play different roles and we all play those roles to the best of our abilities, but we have to recognize we do have groups with very large stakes in this process.